Pharmacokinetic/Pharmacodynamic Evaluation Amikacin in Critically Ill Patients Admitted at the Emergency Department

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is the evaluation of PK/PD target attainment of amikacin in ED patients with severe sepsis and septic shock.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universitaire Ziekenhuizen Leuven
• Treatments: Amikacin

Criteria

Inclusion Criteria:

• patients admitted at the emergency department with a diagnosis of severe sepsis or septic shock in whom amikacin is indicatied

Exclusion Criteria:

• < 18 years

• pregnancy

• burns

• amikacin treatment in the previous 2 weeks

• known allergy to aminoglycosides

• Do Not Reanimate Code ≥ 2

• Hospitalized patients with a prolonged deep venous or arterial catheder

• Continuous renal replacement, intermittent hemodialysis and death within the time of start of amikacin replacement and 1 hour later